beginner8 min read

What Is an FDA Clinical Hold?

Reviewed by Blane Jackson, DDS, MBA. Educational guide only. See the editorial policy and disclosures.

Imagine you're watching a biotech company you've invested in. Their lead drug is in a Phase 2 trial, and everything seems on track. Then, out of nowhere, the company announces that the FDA has placed a 'clinical hold' on the trial. The stock drops 30% in a day. What just happened? An FDA clinical hold is a formal order from the FDA to pause a clinical trial. It can happen at any stage, for a variety of reasons, and it can be a major setback for the company and its investors. In this guide, we'll break down what a clinical hold is, what triggers one, how long it typically lasts, and what it means for the stock. You'll learn how to interpret the news and what questions to ask to assess the impact on your investment.

What Exactly Is an FDA Clinical Hold?

An FDA clinical hold is an order issued by the FDA to delay or suspend a clinical trial. It's not a rejection of the drug itself, but rather a pause to address specific concerns about patient safety or trial conduct. The FDA can issue a hold for a new trial before it starts (a 'pre-IND' hold) or for an ongoing trial. When a hold is placed, enrollment stops, and current participants may be asked to stop taking the drug or to continue under close monitoring, depending on the nature of the hold. The goal is to protect patients while the sponsor (the company) works to resolve the FDA's concerns. Think of it as a 'timeout' in a game – the game isn't over, but you have to stop and sort things out before you can continue.

Key takeaway

A clinical hold is a pause, not a rejection. It's the FDA's way of saying 'we need more information or changes before you can proceed.'

Example

In 2021, the FDA placed a clinical hold on a gene therapy trial for Duchenne muscular dystrophy by Solid Biosciences after a patient experienced a serious adverse event. The hold was lifted after the company made changes to the trial protocol.

What Triggers an FDA Clinical Hold?

The most common reason for a clinical hold is a safety concern. This could be an unexpected serious adverse event (SAE) in a patient, such as liver toxicity or an unexplained death. The FDA may also issue a hold if new preclinical (animal) data raises questions about the drug's safety. Other triggers include: inadequate patient informed consent forms, missing or incomplete data in the IND (Investigational New Drug) application, manufacturing issues with the drug product, or a failure to follow the trial protocol. In some cases, a hold can be placed due to a lack of efficacy – if the drug is clearly not working, the FDA may stop the trial to avoid exposing patients to a useless treatment. However, safety is the primary concern.

Key takeaway

Safety issues are the #1 trigger for a clinical hold, but administrative and manufacturing problems can also cause holds.

Example

In 2016, Juno Therapeutics' CAR-T therapy trial was placed on hold after two patient deaths from cerebral edema. The hold was lifted after the company modified the treatment regimen.

Ready to start? Open a Webull account and trade biotech stocks commission-freevia Webull · Affiliate

How Long Do Clinical Holds Last?

The duration of a clinical hold varies widely. Some holds are resolved in a few weeks, while others can last months or even years. The timeline depends on the complexity of the FDA's concerns and how quickly the company can address them. The FDA typically responds to a company's response within 30 days, but if the issues are serious, the company may need to conduct additional studies or make major changes to the trial design, which takes time. In some cases, a hold may be permanent if the risks outweigh the benefits. For investors, it's important to note that the longer the hold, the more detrimental it is to the company's timeline and financial resources.

Key takeaway

Clinical holds can last from weeks to years. The longer the hold, the more serious the underlying issues and the greater the impact on the company.

Example

In 2020, the FDA placed a clinical hold on a trial for a Duchenne muscular dystrophy gene therapy by Sarepta Therapeutics. The hold lasted about 3 months before being lifted after the company provided additional data.

What Does a Clinical Hold Mean for a Biotech Stock?

A clinical hold is almost always bad news for a biotech stock, at least in the short term. The stock often drops significantly on the announcement, as investors worry about the potential delay, increased costs, and the possibility that the drug may never make it to market. The magnitude of the drop depends on how much of the company's value is tied to the specific drug, the stage of development, and the perceived severity of the hold. For example, a hold on a Phase 3 trial for a company's only drug candidate could be devastating, while a hold on an early-stage trial for a company with a diversified pipeline might be less impactful. However, some stocks recover if the hold is lifted quickly and the underlying safety concerns are resolved. It's also important to note that a clinical hold can sometimes be a buying opportunity if you believe the issues are minor and the company has the resources to overcome them.

Key takeaway

A clinical hold typically causes a stock drop, but the long-term impact depends on the severity and duration of the hold, and the company's ability to resolve it.

Example

When the FDA placed a clinical hold on Intercept Pharmaceuticals' Ocaliva for a liver disease in 2023, the stock fell over 20%. However, the hold was lifted a few months later, and the stock partially recovered.

How to Evaluate a Clinical Hold Announcement

When you hear about a clinical hold, don't panic. Instead, take a systematic approach to assess the situation. First, read the company's press release carefully. Look for the reason for the hold – is it a safety issue, a manufacturing problem, or something else? Second, check the stage of the trial and how important it is to the company's pipeline. Third, look for any details about what the company plans to do to address the hold. Fourth, consider the company's cash runway – can it survive a prolonged delay? Finally, look for expert opinions or analyses from credible sources. Remember, the market often overreacts to clinical holds, so a well-informed investor can find opportunities.

Key takeaway

Don't just look at the stock price – dig into the details of the hold to understand its true impact.

Example

In 2022, a clinical hold on a trial for a rare disease drug by a small biotech caused a 50% drop, but the hold was lifted in 2 weeks after a minor protocol amendment. Investors who recognized the low risk could have bought at a discount.

Key terms

Clinical Hold

An order from the FDA to delay or suspend a clinical trial. It is not a rejection of the drug but a pause to address safety or other issues.

IND (Investigational New Drug) Application

A request to the FDA to allow a company to test a new drug in humans. It includes preclinical data and trial protocols.

Adverse Event (AE)

Any unfavorable or unintended medical occurrence in a patient during a clinical trial, whether or not it is related to the drug.

Serious Adverse Event (SAE)

An adverse event that results in death, is life-threatening, requires hospitalization, or causes significant disability.

Protocol

The detailed plan for a clinical trial, including objectives, design, methodology, and statistical considerations.

Cash Runway

The length of time a company can continue to operate before it runs out of cash, based on its current spending rate.

Next steps

If a company you own announces a clinical hold, read the full press release and any FDA statements to understand the exact reason.

Check the company's cash runway to see if it can survive a prolonged hold without needing to raise capital at a low stock price.

Look for the company's plan to resolve the hold – do they have a timeline? Are they conducting additional studies?

Monitor the stock for a potential buying opportunity if you believe the hold is minor and the company is well-positioned to resolve it quickly.

Review the company's pipeline to see if other drugs are in development that could offset the impact of the hold.

Put this guide to work

Use these free ClinicalInvestor tools to apply what you just learned.

2026 PDUFA Calendar →

Every FDA decision in 2026 with AI investor analysis.

Biotech Catalyst Calendar →

PDUFA dates, Phase 3 readouts, AdComs, and conferences. Free.

Trial Translator →

Paste any ClinicalTrials.gov ID and get a plain-English AI breakdown.

Biotech Screener →

Filter published biotech profiles by area, phase, market cap, and runway.

Company Profiles →

Pipelines, bull and bear cases, and next expected data for every covered biotech.

Keep learning

Clinical Trial Phases Explained →Understanding Cash Runway in Biotech Stocks →Biotech Risk Management →